Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about prostate cancer awareness and the FDA’s approval of a new pain medication. He also explains a study that ...

Unnecessarily high doses not only increase risk of complications and adverse effects associated with the drug but increase hospital costs. Certainly, more studies will be required to define the best ...

The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system, preventing pain signals from reaching the brain. The approval marks the first new ...

The U.S. Food and Drug Administration signed off Thursday on the first new type of pain reliever ... taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts.

TLX007-CDx, a PSMA-PET imaging agent for prostate cancer, may offer an extended distribution profile compared to current agents, with an FDA decision expected by March 24, 2025. Gepotidacin, a ...